Cargando…

Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients

BACKGROUND: Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive fibrosis of the skin and the internal organs. In a previous work we suggested a correlation between levels of salivary psoriasin (S100A7) and pulmonary involvement in SSc patients. The goals of this study are...

Descripción completa

Detalles Bibliográficos
Autores principales: Giusti, Laura, Sernissi, Francesca, Donadio, Elena, Ciregia, Federica, Giacomelli, Camillo, Giannaccini, Gino, Mazzoni, Maria Rosa, Lucacchini, Antonio, Bazzichi, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015208/
https://www.ncbi.nlm.nih.gov/pubmed/27608975
http://dx.doi.org/10.1186/s12967-016-1023-5
_version_ 1782452391759577088
author Giusti, Laura
Sernissi, Francesca
Donadio, Elena
Ciregia, Federica
Giacomelli, Camillo
Giannaccini, Gino
Mazzoni, Maria Rosa
Lucacchini, Antonio
Bazzichi, Laura
author_facet Giusti, Laura
Sernissi, Francesca
Donadio, Elena
Ciregia, Federica
Giacomelli, Camillo
Giannaccini, Gino
Mazzoni, Maria Rosa
Lucacchini, Antonio
Bazzichi, Laura
author_sort Giusti, Laura
collection PubMed
description BACKGROUND: Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive fibrosis of the skin and the internal organs. In a previous work we suggested a correlation between levels of salivary psoriasin (S100A7) and pulmonary involvement in SSc patients. The goals of this study are to determine the distribution characteristics of psoriasin in whole saliva (WS) of SSc and healthy donor populations and define its predictive value on diffusion capacity of carbon monoxide (DLCO), along with others clinical parameters. METHODS: Salivary level of psoriasin was determined by ELISA kit in 134 SSc patients, 63 Raynaud syndrome patients, 40 patients affected by other connective diseases (non-case) and 74 healthy control subjects. RESULTS: A significant increase of salivary psoriasin was observed in SSc patients when compared with other healthy and pathological controls. Moreover, we confirmed the efficacy of salivary psoriasin to correlate with DLCO in a large cohort of SSc patients. CONCLUSIONS: Overall our results suggest a rapid, non invasive and low costing method which can help clinicians in the evaluation of SSc pulmonary involvement.
format Online
Article
Text
id pubmed-5015208
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50152082016-09-09 Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients Giusti, Laura Sernissi, Francesca Donadio, Elena Ciregia, Federica Giacomelli, Camillo Giannaccini, Gino Mazzoni, Maria Rosa Lucacchini, Antonio Bazzichi, Laura J Transl Med Research BACKGROUND: Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive fibrosis of the skin and the internal organs. In a previous work we suggested a correlation between levels of salivary psoriasin (S100A7) and pulmonary involvement in SSc patients. The goals of this study are to determine the distribution characteristics of psoriasin in whole saliva (WS) of SSc and healthy donor populations and define its predictive value on diffusion capacity of carbon monoxide (DLCO), along with others clinical parameters. METHODS: Salivary level of psoriasin was determined by ELISA kit in 134 SSc patients, 63 Raynaud syndrome patients, 40 patients affected by other connective diseases (non-case) and 74 healthy control subjects. RESULTS: A significant increase of salivary psoriasin was observed in SSc patients when compared with other healthy and pathological controls. Moreover, we confirmed the efficacy of salivary psoriasin to correlate with DLCO in a large cohort of SSc patients. CONCLUSIONS: Overall our results suggest a rapid, non invasive and low costing method which can help clinicians in the evaluation of SSc pulmonary involvement. BioMed Central 2016-09-08 /pmc/articles/PMC5015208/ /pubmed/27608975 http://dx.doi.org/10.1186/s12967-016-1023-5 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Giusti, Laura
Sernissi, Francesca
Donadio, Elena
Ciregia, Federica
Giacomelli, Camillo
Giannaccini, Gino
Mazzoni, Maria Rosa
Lucacchini, Antonio
Bazzichi, Laura
Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients
title Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients
title_full Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients
title_fullStr Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients
title_full_unstemmed Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients
title_short Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients
title_sort salivary psoriasin (s100a7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015208/
https://www.ncbi.nlm.nih.gov/pubmed/27608975
http://dx.doi.org/10.1186/s12967-016-1023-5
work_keys_str_mv AT giustilaura salivarypsoriasins100a7correlateswithdiffusioncapacityofcarbonmonoxideinalargecohortofsystemicsclerosispatients
AT sernissifrancesca salivarypsoriasins100a7correlateswithdiffusioncapacityofcarbonmonoxideinalargecohortofsystemicsclerosispatients
AT donadioelena salivarypsoriasins100a7correlateswithdiffusioncapacityofcarbonmonoxideinalargecohortofsystemicsclerosispatients
AT ciregiafederica salivarypsoriasins100a7correlateswithdiffusioncapacityofcarbonmonoxideinalargecohortofsystemicsclerosispatients
AT giacomellicamillo salivarypsoriasins100a7correlateswithdiffusioncapacityofcarbonmonoxideinalargecohortofsystemicsclerosispatients
AT giannaccinigino salivarypsoriasins100a7correlateswithdiffusioncapacityofcarbonmonoxideinalargecohortofsystemicsclerosispatients
AT mazzonimariarosa salivarypsoriasins100a7correlateswithdiffusioncapacityofcarbonmonoxideinalargecohortofsystemicsclerosispatients
AT lucacchiniantonio salivarypsoriasins100a7correlateswithdiffusioncapacityofcarbonmonoxideinalargecohortofsystemicsclerosispatients
AT bazzichilaura salivarypsoriasins100a7correlateswithdiffusioncapacityofcarbonmonoxideinalargecohortofsystemicsclerosispatients